Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study

J Clin Oncol. 2009 Feb 10;27(5):726-32. doi: 10.1200/JCO.2008.18.3228. Epub 2008 Dec 29.

Abstract

Purpose: To determine the detection rate, the false-negative rate, and the accuracy of sentinel lymph node (SLN) detection after neoadjuvant chemotherapy (NAC) for advanced breast cancer.

Patients and methods: A prospective multicentric study was initiated to evaluate the results of SLN biopsy with the combined method after NAC for advanced large operable breast cancer.

Results: From September 2003 to March 2007, 195 patients enrolled from 12 institutions were found suitable for evaluation. The detection rate was 90% (176 of 195 patients), and the false-negative rate was 11.5% (six of 52 patients). Patients without axillary palpable nodes (N0) before NAC had a better detection rate compared with patients with axillary suspicious nodes (N1, 94.6% v 81.5%; P = .008). The false-negative rate was not correlated with clinical nodal status before NAC (9.4% v 15%; P = .66).

Conclusion: This study confirms the feasibility of SLN biopsy after NAC in the case of large operable breast cancer. The detection rate, false-negative rate, and accuracy do not differ from those obtained in the case of early breast cancer without NAC, thus demonstrating the feasibility of SLN biopsy after NAC.

Publication types

  • Multicenter Study

MeSH terms

  • Axilla
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • False Negative Reactions
  • Feasibility Studies
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Prospective Studies
  • Sentinel Lymph Node Biopsy* / methods